Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

Ferlay, 2007, Estimates of the cancer incidence and mortality in Europe in 2006, Ann Oncol, 18, 581, 10.1093/annonc/mdl498 Karumanchi, 2002, Renal cancer: molecular mechanisms and newer therapeutic options, Curr Opin Nephrol Hypertens, 11, 37, 10.1097/00041552-200201000-00006 DeVita, 2001 Motzer, 1996, Renal-cell carcinoma, N Engl J Med, 335, 865, 10.1056/NEJM199609193351207 Rouviere, 2006, Nonmetastatic renal cell carcinoma: is it really possible to define rational guidelines for post treatment follow up, Nat Clin Pract Oncol, 3, 200, 10.1038/ncponc0479 Rini, 2005, Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma, J Clin Oncol, 23, 1028, 10.1200/JCO.2005.01.186 Brieger, 1999, Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumors, J Mol Med, 77, 505, 10.1007/s001099900022 Gabrilovich, 1999, Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function, Clin Cancer Res, 5, 2963 Schoenfeld, 2000, The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis, Oncogene, 19, 5851, 10.1038/sj.onc.1203985 Coppin, 2005, Immunotherapy for advanced renal cell cancer, Cochrane Database Syst Rev, 3 Parton, 2006, Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer, J Clin Oncol, 24, 5584, 10.1200/JCO.2006.08.1638 Motzer, 2002, Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma, J Clin Oncol, 20, 289, 10.1200/JCO.2002.20.1.289 Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N Engl J Med, 356, 125, 10.1056/NEJMoa060655 Ratain, 2006, Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma, J Clin Oncol, 24, 2505, 10.1200/JCO.2005.03.6723 Motzer, 2006, Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma, J Clin Oncol, 24, 16, 10.1200/JCO.2005.02.2574 Motzer, 2006, Sunitinib in patients with metastatic renal cell carcinoma, JAMA, 295, 2516, 10.1001/jama.295.21.2516 Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med, 356, 115, 10.1056/NEJMoa065044 Hudes, 2007, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma, N Engl J Med, 356, 2271, 10.1056/NEJMoa066838 Yang, 2003, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer, N Engl J Med, 349, 427, 10.1056/NEJMoa021491 Bukowski, 2006, Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC), J Clin Oncol, 24, 222s Yang, 2004, Bevacizumab for patients with metastatic renal cancer: an update, Clin Cancer Res, 10, 6367S, 10.1158/1078-0432.CCR-050006 Hainsworth, 2005, Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib, J Clin Oncol, 23, 7889, 10.1200/JCO.2005.01.8234 Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691 Miller, 2005, A randomised phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer, Breast Cancer Res Treat, 94, S6 Sandler, 2006, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer, N Engl J Med, 355, 2542, 10.1056/NEJMoa061884 Thompson, 2006, Bevacizumab, erlotinib and imatinib in the treatment of patients with advanced renal cell carcinoma: update of a multicenter phase II trial, J Clin Oncol, 24, 240s Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205 2002 2003 DeMets, 1994, Interim analysis: the alpha spending function approach, Stat Med, 13, 1341, 10.1002/sim.4780131308 Dutcher, 2007, Correlation of survival of tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon-alpha, J Clin Oncol, 25, 5033, 10.1200/jco.2007.25.18_suppl.5033 Negrier, 2005, Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial, J Clin Oncol, 23, 380s Ramsey, 2006, Treatment for renal cancer: are we beyond the cytokine era?, Nat Clin Pract Urol, 3, 478, 10.1038/ncpuro0581 Donskov, 2006, Impact of immune parameters on long-term survival in metastatic renal cell carcinoma, J Clin Oncol, 24, 1997, 10.1200/JCO.2005.03.9594 Jonasch, 2001, Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities, Oncologist, 6, 34, 10.1634/theoncologist.6-1-34 Eggermont, 2007, EORTC 18991: long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial, J Clin Oncol, 25, 473s Tournigand, 2004, FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study, J Clin Oncol, 22, 229, 10.1200/JCO.2004.05.113 George, 2007, Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): updated results and analysis of circulating biomarkers, J Clin Oncol, 25, 243s Drabkin, 2007, The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with prior bevacizumab (BEV) treatment, J Clin Oncol, 25, 245s Sablin, 2007, Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients, J Clin Oncol, 25, 244s Feldman, 2007, Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC), J Clin Oncol, 25, 259s Azad, 2006, Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab, J Clin Oncol, 24, 121s Merchan, 2007, Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results, J Clin Oncol, 25, 243s